United Therapeutics バランスシートの健全性
財務の健全性 基準チェック /66
United Therapeuticsの総株主資本は$6.1B 、総負債は$400.0Mで、負債比率は6.6%となります。総資産と総負債はそれぞれ$7.1Bと$1.0Bです。 United Therapeuticsの EBIT は$1.3Bで、利息カバレッジ比率-8.9です。現金および短期投資は$3.3Bです。
主要情報
6.6%
負債資本比率
US$400.00m
負債
| インタレスト・カバレッジ・レシオ | -8.9x |
| 現金 | US$3.33b |
| エクイティ | US$6.10b |
| 負債合計 | US$1.02b |
| 総資産 | US$7.12b |
財務の健全性に関する最新情報
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04財務状況分析
短期負債: UTHRの 短期資産 ( $4.0B ) が 短期負債 ( $873.4M ) を超えています。
長期負債: UTHRの短期資産 ( $4.0B ) が 長期負債 ( $148.8M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: UTHR総負債よりも多くの現金を保有しています。
負債の削減: UTHRの負債対資本比率は、過去 5 年間で36.8%から6.6%に減少しました。
債務返済能力: UTHRの負債は 営業キャッシュフロー によって 十分にカバー されています ( 284.2% )。
インタレストカバレッジ: UTHR支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。